$4.95
0.17% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US92829J1043
Symbol
DWTX

Virios Therapeutics Inc Stock price

$4.95
+0.26 5.51% 1M
-0.10 2.01% 6M
+2.46 98.73% YTD
-0.29 5.56% 1Y
-156.55 96.94% 3Y
-245.05 98.02% 5Y
-245.05 98.02% 10Y
-245.05 98.02% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 0.17%
ISIN
US92829J1043
Symbol
DWTX
Industry

Key metrics

Basic
Market capitalization
$9.5m
Enterprise Value
$-3.9m
Net debt
positive
Cash
$13.4m
Shares outstanding
1.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.1
Financial Health
Equity Ratio
68.2%
Return on Equity
-20.0%
ROCE
-19.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-18.2m | -
EBIT
$-18.2m | $-18.8m
Net Income
$-26.5m | $-18.7m
Free Cash Flow
$-15.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-234.3% | -53.4%
Net Income
-400.2% | -45.2%
Free Cash Flow
-276.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-13.9
FCF per Share
$-8.2
Short interest
6.8%
Employees
-
Rev per Employee
-
Show more

Is Virios Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Virios Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Virios Therapeutics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Virios Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Virios Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
178% 178%
-
- Research and Development Expense 7.86 7.86
280% 280%
-
-18 -18
-
-
- Depreciation and Amortization 0.05 0.05
-
-
EBIT (Operating Income) EBIT -18 -18
234% 234%
-
Net Profit -27 -27
400% 400%
-

In millions USD.

Don't miss a Thing! We will send you all news about Virios Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Virios Therapeutics Inc Stock News

Neutral
GlobeNewsWire
11 days ago
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2025 - - Low discontinuation rate (5.8%) due to adverse events in the first 38 patients completing the trial suggests Halneuron ® and placebo treatment have been generally well tolerated - - Cash on...
Neutral
GlobeNewsWire
17 days ago
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -
Neutral
GlobeNewsWire
18 days ago
ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, announced today that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 before the open of the financial markets.
More Virios Therapeutics Inc News

Company Profile

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.

Head office United States
CEO Gregory Duncan
Founded 2012
Website dwtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today